Ira Spector
Vorstandsvorsitzender bei SFA Therapeutics, Inc.
Profil
Ira Spector is currently the Chief Executive Officer at SFA Therapeutics, Inc. Previously, he worked as the Executive Vice President-Analytics & Consulting at ICON plc.
He completed his undergraduate degree at Washington University in St. Louis, his doctorate at the University of Medicine & Dentistry of New Jersey, and his MBA at Drexel University.
Aktive Positionen von Ira Spector
| Unternehmen | Position | Beginn |
|---|---|---|
SFA Therapeutics, Inc.
 SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Vorstandsvorsitzender | 01.08.2017 |
Ehemalige bekannte Positionen von Ira Spector
| Unternehmen | Position | Ende |
|---|---|---|
| ICON PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Ausbildung von Ira Spector
| University of Medicine & Dentistry of New Jersey | Doctorate Degree |
| Drexel University | Masters Business Admin |
| Washington University in St. Louis | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ICON PUBLIC LIMITED COMPANY | Commercial Services |
| Private Unternehmen | 1 |
|---|---|
SFA Therapeutics, Inc.
SFA Therapeutics, Inc. Packaged SoftwareTechnology Services SFA Therapeutics, Inc. is a clinical-stage biotech company based on breakthrough research of the human microbiome licensed from Temple University. SFA Therapeutics is located in Jenkintown, PA. Ira Spector has been the CEO of the company since 2017. The company is developing a platform of safer therapeutics focused on the treatment of inflammatory diseases, targeting NF-kB and RAS. SFA has identified six small molecule drug candidates from this platform, including its lead asset, SFA-002, which has shown promising phase 1a results and is currently being investigated in a phase 1b study for psoriasis. The company's research program is focused on the intersection of chronic inflammation and cancer. | Technology Services |
